Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, November 4, 4:30 p.m. Eastern Time BRISBANE, Calif., Nov. 04, ...